-
Identifying risks for early onset pre-eclampsia.
Kraus M, Nicolaides K.
Womens Health (Lond) 2015;11:15-7. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Kagan KO, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:42-7. pdf -
Fetal fraction of cell-free DNA in maternal plasma in the prediction of spontaneous preterm delivery.
Quezada MS, Francisco C, Dumitrascu-Biris D, Nicolaides KH, Poon LC.
Ultrasound Obstet Gynecol 2015;45:101-5. pdf -
Competing risks model in screening for preeclampsia by maternal characteristics and medical history.
Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2015;213:62.e1-62.e10. pdf -
Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis.
Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:249-66. pdf -
Maternal serum anti-Mallerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia.
Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC.
J Matern Fetal Neonatal Med 2015;28:865-8. pdf -
Glycosaminoglycans and proteoglycans in the skin of aneuploid fetuses with increased nuchal translucency.
von Kaisenberg CS, Prols F, Nicolaides KH, Maass N, Meinhold-Heerlein I, Brand-Saberi B.
Hum Reprod 2003;18:2544-61. -
Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy.
Spencer K, Bindra R, Nicolaides KH.
Prenat Diagn 2003;23:851-5. -
Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester?
Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:142-8. -
Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience.
Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH.
BJOG 2003;110:281-6. -
Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K, Nicolaides KH.
BJOG 2003;110:276-80. -
Nasal bone length throughout gestation: normal ranges based on 3537 fetal ultrasound measurements.
Sonek JD, McKenna D, Webb D, Croom C, Nicolaides K.
Ultrasound Obstet Gynecol 2003;21:152-5. -
Ear length in trisomy 21 fetuses at 11-14 weeks of gestation.
Sacchini C, El-Sheikhah A, Cicero S, Rembouskos G, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:460-3. -
Single umbilical artery at 11-14 weeks' gestation: relation to chromosomal defects.
Rembouskos G, Cicero S, Longo D, Sacchini C, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:567-70. -
Fetal loss following ultrasound diagnosis of a live fetus at 6-10 weeks of gestation.
Makrydimas G, Sebire NJ, Lolis D, Vlassis N, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:368-72. -
Megacystis at 10-14 weeks of gestation: chromosomal defects and outcome according to bladder length.
Liao AW, Sebire NJ, Geerts L, Cicero S, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;21:338-41. -
Sonographic markers of fetal aneuploidy: a review.
Cicero S, Sacchini C, Rembouskos G, Nicolaides KH.
Placenta 2003;24:S88-98. -
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
Prenat Diagn 2003;23:306-10. -
Absent nasal bone at 11-14 weeks of gestation and chromosomal defects.
Cicero S, Longo D, Rembouskos G, Sacchini C, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:31-5. -
Learning curve for sonographic examination of the fetal nasal bone at 11-14 weeks.
Cicero S, Dezerega V, Andrade E, Scheier M, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:135-7.